GlassScriptPhysician profile
Anshul M Rao
NPI 1811036817
$4,401.55
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,004 · 2020: $716 · 2021: $882 · 2022: $1,033 · 2023: $418 · 2024: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.09 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $826.53 | 2019-2024 | Enbrel, Otezla, Repatha |
| Pfizer INC. | $576.83 | 2019-2023 | |
| Abbvie INC. | $532.74 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $351.60 | 2019-2024 | |
| Novo Nordisk INC | $249.65 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $226.48 | 2019-2023 | Benlysta |
| Ucb, INC. | $225.95 | 2019-2022 | |
| Janssen Biotech, INC. | $212.36 | 2019-2023 | Stelara, Remicade, Simponi |
| Lilly USA, LLC | $192.94 | 2019-2023 | Taltz |
| Regeneron Healthcare Solutions, INC. | $129.83 | 2019 | |
| Mallinckrodt Hospital Products INC. | $99.91 | 2022-2023 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $95.98 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $92.12 | 2022-2023 | Saphnelo |
| Genentech USA, INC. | $86.43 | 2019-2020 | |
| Organon LLC | $73.65 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $72.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.44 | 2021-2023 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Exact Sciences Corporation | $45.62 | 2023-2024 | Cologuard Collection Kit |
| Radius Health, INC. | $44.48 | 2023-2024 | Tymlos |
| Aurinia Pharma U.S., INC. | $29.94 | 2024 | Lupkynis |
| Lundbeck LLC | $18.90 | 2023 | Vyepti |
| Mallinckrodt Enterprises LLC | $18.72 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.01 | 2024 | Trintellix |
| Acorda Therapeutics, INC | $16.72 | 2021 | |
| Merck Sharp & Dohme LLC | $16.43 | 2020 | |
| Medexus Pharma, INC. | $16.29 | 2019 | |
| Bausch Health US, LLC | $16.00 | 2019 | |
| Emd Serono, INC. | $14.66 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.81 | 2019 | |
| Sandoz INC. | $12.71 | 2022 | |
| Neurelis, INC. | $12.34 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anshul Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.